Dr Kim Nguyen Chi speaks to ecancer about the CCTG PR.21 phase II randomised trial that directly compares 177Lu-PSMA-617 (LU-P), a radioligand therapy targeting PSMA, with docetaxel (DOC) chemotherapy in chemotherapy-naïve patients.

The study found that while radiographic progression-free survival was similar, 177Lu-PSMA-617 demonstrated superior PSA response and lower toxicity, suggesting a meaningful role in preserving quality of life.

However Dr Chi highlights that overall survival favoured docetaxel, highlighting a potential trade-off between disease control and long-term outcomes.

He concludes by saying that these data support the need for personalised treatment approaches in mCRPC based on patient goals, disease biology, and tolerance.

See experts discuss more on prostate cancer here.